000078913 001__ 78913
000078913 005__ 20200113145614.0
000078913 0247_ $$2doi$$a10.1016/j.jpba.2018.04.019
000078913 0248_ $$2sideral$$a106400
000078913 037__ $$aART-2018-106400
000078913 041__ $$aeng
000078913 100__ $$aPires, F.
000078913 245__ $$aA rapid magnetic particle-based enzyme immunoassay for human cytomegalovirus glycoprotein B quantification
000078913 260__ $$c2018
000078913 5060_ $$aAccess copy available to the general public$$fUnrestricted
000078913 5203_ $$aHuman cytomegalovirus (HCMV) is a herpes virus that can cause severe infections. Still, the available methods for its diagnostic have the main disadvantage of requiring long time to be performed. In this work, a simple magnetic particle-based enzyme immunoassay (mpEIA) for the quantification of glycoprotein B of Human cytomegalovirus (gB-HCMV) in urine samples is proposed. The immunosensor scheme is based on the analyte protein gB-HCMV sandwiched between a primary monoclonal antibody, (MBs-PrG-mAb1), and a secondary anti-gB-HCMV antibody labelled with Horseradish peroxidase (Ab2-HRP) to allow spectrophotometric detection. The mpEIA analytical performance was tested in urine samples, showing a linear dependence between gB-HCMV concentration and the absorbance signal at 450 nm in a range of concentrations from 90 to 700 pg mL-1. The calculated detection limits for gB-HCMV were 90 ± 2 pg mL-1 and the RSD was about 6.7% in urine samples. The immunosensor showed good selectivity against other viruses from Herpesviridae family, namely varicella zoster and Epstein Barr viruses. The recoveries of spiked human urine samples at 0.30–0.50 ng mL-1 concentration levels of gB-HCMV ranged between 91 to 105%. The proposed mpEIA method was validated following the guidelines of the European Medicines Agency (EMEA-2014), and allows rapid, successful and easy quantification of gB-HCMV in urine samples.
000078913 536__ $$9info:eu-repo/grantAgreement/ES/FEDER/POCI-01-0145-007491$$9info:eu-repo/grantAgreement/ES/MINECO-FEDER/MUSSEL-RTC-2015-4077-2$$9info:eu-repo/grantAgreement/ES/MINECO-FEDER/TEC20013-40561-P
000078913 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000078913 590__ $$a2.983$$b2018
000078913 591__ $$aPHARMACOLOGY & PHARMACY$$b105 / 266 = 0.395$$c2018$$dQ2$$eT2
000078913 591__ $$aCHEMISTRY, ANALYTICAL$$b24 / 84 = 0.286$$c2018$$dQ2$$eT1
000078913 592__ $$a0.786$$b2018
000078913 593__ $$aAnalytical Chemistry$$c2018$$dQ1
000078913 593__ $$aClinical Biochemistry$$c2018$$dQ1
000078913 593__ $$aSpectroscopy$$c2018$$dQ1
000078913 593__ $$aPharmaceutical Science$$c2018$$dQ1
000078913 593__ $$aDrug Discovery$$c2018$$dQ1
000078913 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000078913 700__ $$aArcos-Martinez, M.J.
000078913 700__ $$aDias-Cabral, A.C.
000078913 700__ $$0(orcid)0000-0003-4599-796X$$aVidal, J.C.$$uUniversidad de Zaragoza
000078913 700__ $$0(orcid)0000-0002-4070-8607$$aCastillo, J.R.$$uUniversidad de Zaragoza
000078913 7102_ $$12009$$2750$$aUniversidad de Zaragoza$$bDpto. Química Analítica$$cÁrea Química Analítica
000078913 773__ $$g156 (2018), 372-378$$pJ. pharm. biomed. anal.$$tJournal of Pharmaceutical and Biomedical Analysis$$x0731-7085
000078913 8564_ $$s412528$$uhttps://zaguan.unizar.es/record/78913/files/texto_completo.pdf$$yPostprint
000078913 8564_ $$s45280$$uhttps://zaguan.unizar.es/record/78913/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000078913 909CO $$ooai:zaguan.unizar.es:78913$$particulos$$pdriver
000078913 951__ $$a2020-01-13-14:52:23
000078913 980__ $$aARTICLE